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Abstract
Background: The current economic constraints cause hospital management to use the available public resources as 
rationally as possible. At the same time, there is the necessity to improve current scientific knowledge. This is even 
more relevant in the case of patients with malignant pleural mesothelioma (MPM), given the severity of the disease, 
its dismal prognosis, and the cost of chemotherapy drugs. This work aims to evaluate the standard cost of patients 
with MPM, supporting physicians in their decision-making process in relation to budget constraints, as well as policy-
makers with respect research policy. 
Methods: The authors conducted a retrospective cost analysis on all the patients with MPM who were first admitted to 
a reference hospital specialized in MPM care between 2014 and 2015, collecting data on their diagnostic pathways and 
active treatments, as well as on the related official fees for each procedure. Then, using a multiple regression model, 
we estimated the overall expected cost of a patient with MPM treated in our hospital, to be born by the Regional 
Healthcare System based on the chosen clinical pathway. 
Results: According to results, the economic impact of caring for a patient with MPM is mostly related to the selected 
active treatments, with drug and hospitalization costs as main drivers. Our analysis suggests that the expected 
reimbursed fee to care for a patient with MPM is equal to € 18 214.99, with chemotherapy and monitoring costs equal 
to € 12 861.43 and hospitalization cost equal to € 5353.55. This cost decreases to € 320.18 in the case of enrollment 
in an experimental trial of first-line treatment. In the other cases (second-line or third-line trials), the expected cost 
borne by the healthcare system for treating patients grows exponentially (€ 40,124.18 and € 59 839.94, respectively). 
Conclusion: Experimental trials might be a solution to decrease the economic burden for the public healthcare system 
only in the case of first-line treatments, where the cost of chemotherapy is relevant. Nevertheless, policy-makers have 
to accept the sharing of this economic burden between society and the pharmaceutical industry to broaden the current 
scientific knowledge.
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Implications for policy makers
• Drug cost avoidance might be positive but, in order to properly estimate the economic impact of clinical trials on public healthcare systems, we 
also need to consider alternative standard treatments along the entire clinical pathway of the research subjects.
• Even if experimental treatments might represent an opportunity to increase scientific knowledge and the research subjects’ expected survival 
time, society has to share with pharmaceutical companies a portion of the costs needed to test the proposed innovations and, by doing so, to 
collect clinical evidence.
Implications for the public
The current economic constraints cause hospital management to use the available public resources as rationally as possible. At the same time, there 
is the necessity to improve current scientific knowledge. Pharmaceutical clinical research might be an opportunity to face these issues, especially in 
those rare tumors characterized by dismal prognosis and significant cost of chemotherapy drugs. 
According to the results of this work, experimental trials might be a solution to decrease the economic burden for the public healthcare system only 
in some cases. Therefore, in order to expand medical knowledge, society needs not only to accept the pharmaceutical companies’ market power (ie, 
monopoly) and a part of the adverse risks linked to clinical research but also to bear the additional economic costs related to the testing phase. This 
is the price to be paid if we want to win the battle against rare tumors. 
Key Messages 
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Background
Malignant pleural mesothelioma (MPM) is an aggressive 
tumor predominantly arising in the pleural cavity and related 
to asbestos exposure. Despite the extensive use of asbestos 
since the end of the Second World War, which has produced 
a significant increase in incidence and mortality among the 
population of industrialized countries, MPM is considered a 
rare tumor, with an estimated incidence of 3.5/100.000/y in 
males and 1.3/100.000/y in females. However, in contaminated 
areas, the incidence rises to 10 to 20 times above the expected 
rate. MPM prognosis is very poor and average survival is 
between 9 and 12 months after diagnosis.1
Italy was an important asbestos producer and user until 
its prohibition in 1992, with a peak of about 3 748 550 tons 
of row asbestos consumption between 1976 and 1980. In 
particular, asbestos was used in several industrial activities, 
such as the chemical industry, steel industry, metalworking, 
construction of railroad cars and ships, and cement industry.2 
According to Italian epidemiological studies, the incidence of 
MPM is due to occupational and non-occupational exposure 
(eg, environmental and domestic exposure), with an overall 
higher mortality risk for the population living near asbestos-
cement plants, like in the North West of Italy. In particular, 
one of the main active asbestos-cement factories (ie, Eternit) 
was located in Casale Monferrato, branding this area as one 
of the most asbestos polluted. Indeed, this area displays the 
highest incidence of MPM cases.3
MPM and its management are considered a serious public 
health problem, also representing a major challenge for the 
finances of the regional public healthcare system. Despite 
being unsuccessful, the existing chemotherapy treatments 
are extremely expensive. The current austerity approach only 
makes it more difficult for hospital managers to keep within 
their budget constraints while, at the same time, offering 
an appropriate supply of cancer treatments to patients with 
MPM. On the one hand, society needs to advance the current 
scientific knowledge, identifying innovative successful 
treatments. On the other hand, budget constraints lead 
hospital managers to search for alternatives to existing, highly 
priced chemotherapy, which is even more relevant if we 
consider the current worldwide period of austerity and the 
widespread spending review policy in the healthcare sector.4-6 
Is it admissible to believe that experimental activities might 
represent a solution to these open issues? 
According to the current literature, participating in clinical 
trials would yield clear benefits such as, for example, 
contributing to the advancement of medical research and/
or ensuring access to experimental treatments,7,8 although 
patients would have to share a portion of the risks related 
to these innovative treatments.9 Obviously, this is extremely 
significant in the case of MPM, ie, one of those pathologies 
for which there are no effective clinical alternatives.10 Another 
key reason for participating in clinical trials is that they 
eliminate drug expenditure, which might have a significant 
economic impact on the whole healthcare system,11 its 
hospitals,12,13 pharmacies,14,15 as well as oncology units.16 
Indeed, drugs might be supplied for free by the sponsor of the 
clinical trial, thus bringing about a substantial saving, which 
is even more significant considering the increasing price of 
chemotherapy.17-19 However, there is also evidence against 
this hypothesis, since clinical trials might result in a heavier 
clinical and administrative burden, with a negative economic 
impact on the budget.20-22 
Indeed, when a patient is enrolled in a clinical trial, specific 
medical procedures are necessary (ie, additional checkups, 
blood tests and radiological exams), as well as other non-
treatment trial activities.16,20 This means that the principal 
investigator and his/her collaborators need not only time 
and effort to correctly manage all the duties required by 
the experimental protocol but also additional economic 
resources. This is why pharmaceutical companies provide 
grants as a form of economic compensation for these 
operating costs, even though they might not be sufficient. 
Researchers identify higher expenditure as the main reason 
for the non-activation of trials, reflecting the rising costs 
and complexity of cancer clinical trials.23 Moreover, the 
unexpected toxicity of experimental drugs might increase 
the probability of hospitalization, with a significant growth in 
public expenditure. 
Nevertheless, little research has been carried out on the costs 
of treating patients within clinical trials, taking the whole 
clinical pathway into account. On the one hand, the current 
literature compares experimental treatments (with free drugs) 
to alternative standard treatments (involving a cost), but 
operating costs are not taken into account. On the other hand, 
researchers focus exclusively on operating costs due to the 
higher number of medical activities required by experimental 
protocols. In both cases, the whole clinical pathway is not 
taken into account. In other words, the current literature does 
not indicate whether drug cost avoidance (plus a grant) might 
offset the expected higher operating costs and the unexpected 
toxicity, considering the whole clinical path of these patients 
(ie, from their first access to their death). A micro analysis is 
necessary to properly compare alternative clinical pathways 
and, in this way, shed new light on this key issue.
This work aims to compare clinical pathways, focusing on the 
economic impact of experimental and standard treatments on 
the healthcare system. Standard treatments are understood as 
all those treatments suggested by national and international 
guidelines based on collected clinical evidence, ie, the current 
best answer to MPM, while experimental treatments are all 
those innovative treatments which need clinical evidence to 
be accepted by the scientific community and authorized by the 
National Drug Agency. In particular, although experimental 
treatments can provide innovative ways to cure patients, the 
authors investigate the hypothesis that the economic costs 
needed to treat research subjects might actually be borne 
also by the public healthcare system. In other words, we test 
whether clinical trials might represent a way to save public 
resources or whether there are economic costs which the 
hospital management has to bear to improve scientific medical 
knowledge. The results are not easily predictable since clinical 
trials might represent a saving due to drug cost avoidance but, 
at the same time, they might entail higher operating costs. 
The structure of this paper is as follows. Section two presents 
our data and the adopted methodology, while the results of 
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the empirical analysis are set out in section three. Finally, the 
last section puts forward some conclusions. 
Methods
The authors conducted a retrospective cost analysis on all 
the patients with MPM first admitted to a reference hospital 
specialized in MPM care between 2014 and 2015, focusing on 
those who died before June 2016. Exclusion criteria were only 
non-epithelioid istotype. We collected data about the patients’ 
diagnostic pathways and all the treatments provided by the 
hospital, applying the official regional fees for each procedure 
to estimate their costs (D.D. June 16, 2015, no. 371). Indeed, 
this hospital is a public institution and its activity is reimbursed 
by the regional public healthcare system, according to current 
regulations and applying the cited price list. Then, using a 
multiple regression model, we estimated the overall expected 
cost of treating a patient with MPM in the hospital, which 
would be borne by the regional healthcare system. Finally, 
adopting the estimated coefficients, we implemented a 
simulation to compare clinical pathways with experimental 
and/or standard treatments. 
According to the current national regulations in Italy, patients 
are free to choose their health provider, without paying a 
fee (eg, in case of hospitalization) or, in some cases, paying 
a given fixed contribution (eg, in case of diagnostic exams). 
Obviously, the patients’ choice is driven by the providers’ 
efficiency in offering therapeutic treatments, their quality 
and/or the proposed level of innovation.24 Afterwards, the 
Local Health Authority responsible, on a territorial basis, for 
the health of those patients will reimburse the health provider 
for all the treatments recognized as essential by the Italian 
Ministry of Health (ie, Livelli Essenziali di Assistenza). In 
other words, each of the regional healthcare systems has to 
guarantee its citizens some specific treatments, which might 
be bought on the market or provided directly by the Local 
Health Authority, with a reimbursement system that should 
lead to increased levels of efficiency.25-27 
In our specific case study, an independent public hospital 
supplies treatments to patients with MPM free of charge (ie, 
these treatments are recognized as essential by the Italian 
Ministry of Health) and the Local Health Authority then 
reimburses these activities according to pre-established 
standard fees (ie, treatments are bought on the market at a fixed 
price). These fees have been adopted by the authors to estimate 
the expected costs of treating patients according to different 
clinical pathways, considering all activities. Obviously, the 
proposed fees might be higher or lower than the real costs 
borne by the analyzed independent public hospital but, based 
on the current reimbursement system and the suggested idea 
of efficiency, we can expect general convergence among all 
health providers toward a certain value. In other words, this 
work assumes a competitive market equilibrium in the long 
run with no profit, that is to say, real costs equal to standard 
fees.28,29 Therefore, considering our case study, patients with 
MPM do not bear the cost of the treatments, that is to say, 
there is no income effect behind their decisions concerning 
treatment. Their choices are clearly driven by the opportunity 
to receive innovative (experimental) treatments with greater 
expected effectiveness.24 
Table 1 summarizes antitumoral treatments offered to patients 
with MPM in the selected hospital, highlighting the different 
clinical pathways (ie, standard treatments and/or alternative 
experimental strategies). 
Obviously, the decision to opt for an experimental treatment 
has to be agreed with the patient but the preliminary step 
(ie, proposing alternatives) is a prerogative of the physician. 
Depending on the patient’s characteristics and his/her 
expected side effects tolerability, the physician will suggest the 
best option for each line. This clinical ex-ante evaluation of 
side effects tolerability is mainly based on age and concomitant 
diseases (eg, diabetes, neurological conditions, cardiovascular 
conditions), as well as renal, liver and bone marrow function. 
For example, cisplatin and pemetrexed might be proposed 
for first-line treatment (standard treatment), followed by an 
experimental maintenance study (study NCT01358084), with 
another standard treatment for the second line (gemcitabine) 
and third line (vinorelbine). The choice between cisplatin 
and carboplatin – in combination with pemetrexed – will 
depend on the physician’s evaluation of expected side effects 
tolerability. In this example, the choice of cisplatin may be 
due to better renal function, as suggested by the current 
literature.30,31 Afterwards, the enrollment in the experimental 
maintenance study (study NCT01358084) will depend on the 
inclusion criteria set by the sponsor regarding tolerance to the 
expected toxicity of the innovative drug (ie, research subjects’ 
side effects tolerability).
Clearly, it is not possible to establish a priori which the 
entire clinical path might be, since the patient’s response to 
the therapies ought to be observed step by step. In order to 
compare observations and estimate whether a significant 
saving of public resources might really exist, we need to control 
for patient conditions (eg, cancer stage and/or treatment-
related side effects) potentially affecting the main cost 
components (ie, hospitalization and medical/instrumental 
examinations). In other words, an in-depth analysis must be 
carried out adopting more sophisticated statistical tools to 
estimate whether drug cost avoidance might compensate for 
the greater burden of activities related to the clinical trials, 
controlling for some key conditions. 
We analyzed the selected sample of patients adopting an 
Table 1. Potential Clinical Pathways for Patients With MPM
Line of 
Chemotherapy Standard Treatment
Experimental 
Treatmenta
First line
Cisplatin and pemetrexed
or carboplatin and 
pemetrexed
NCT01907100
(First-line study)
Maintenance line -
 NCT01907100
or NCT01358084 
(Maintenance study)
Second line
Gemcitabine or vinorelbine
or carboplatin and 
gemcitabine
NCT01843374
(Second-line study)
Third line Gemcitabine or vinorelbine NCT02194231
(Third-line study) 
Abbreviation: MPM, malignant pleural mesothelioma.
a See clinicaltrials.gov.
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ordinary least squares (OLS) regression model to evaluate the 
main cost components to be borne by the healthcare system 
for patients affected by MPM, applying the robust option. 
Additional model specifications are also proposed, such as 
a sensitivity analysis, dropping variables, and controlling 
whether the signs of the remaining variables change. The 
proposed approach is coherent with the current literature,22 
estimating a statistically significant weight for every cost 
driver. Then, based on the collected results (ie, the estimated 
weights), ceteris paribus, we compared different clinical 
pathways, focusing on the expected final cost. 
In detail, for every patient, the following control variables are 
proposed:
•	 time (age), which is the age of each of the patients at the 
time of their first medical access (expressed in years); 
•	 time (survival), which is the time between first medical 
access and death (expressed in months);
•	 non-naïve patient, which is a dummy variable equal to 1 
if the patient had already been treated in other medical 
centers, 0 otherwise; 
•	 exit patient, which is a dummy variable equal to 1 if the 
patient left our hospital to be treated in other medical 
centers, 0 otherwise;
•	 cancer stage, which is a categorical variable (values from 
1 to 4) referring to the extent of MPM;
•	 side effects tolerability, which is a dummy variable 
equal to 1 if tolerability to the potential side effects of 
chemotherapy can be expected on the basis of clinical ex-
ante evaluations (eg, considering age and concomitant 
diseases, as well as renal, liver and bone marrow 
function), 0 otherwise;
while, focusing on the explanatory variables, we adopted:
•	 hospitalizations, ie, the number of hospitalizations in our 
oncology unit; 
•	 first line (cycles), which is the number of cycles in the 
first-line treatment, normalized between 0 and 1 (with 
6 cycles as the expected maximum number of cycles in 
this line); 
•	 maintenance (cycles), which is the number of cycles after 
the first-line treatment in order to maintain the achieved 
response status (note that this treatment line is available 
exclusively in experimental strategies);
•	 second line (cycles), which is the number of cycles in 
the second-line treatment, after the first-line treatment 
or after the experimental maintenance treatment (if the 
patient was involved in that trial);
•	 third line (cycles), which is the number of cycles in the 
third-line treatment.
Note that, for the first-line study, we decided to consider the 
expected number of cycles based on the current literature. 
Hence, we estimated the number of implemented cycles in 
relation to the expected number (ie, 6 cycles), so as to consider 
the percentage of adherence to the current guidelines for first-
line studies. Conversely, for what concerns the subsequent 
lines, there is no standard number of cycles.
After that, considering both the standard and the experimental 
treatment, in order to add further information to complement 
the previous variables, we introduced the following additional 
variables into the model:
•	 standard treatment (quota), which is the percentage of 
standard cycles over the total number of cycles supplied 
to the patient (between 0 and 1);
• first-line and maintenance study, which is a dummy 
variable equal to 1 if the patient was involved as a research 
subject in the experimental first-line treatment (ie, study 
NCT01907100), 0 otherwise;
• maintenance study, which is a dummy variable equal 
to 1 if the patient was involved as a research subject 
in the experimental maintenance treatment (ie, study 
NCT01358084), 0 otherwise;
• second-line study, which is a dummy variable equal 
to 1 if the patient was involved as a research subject 
in the experimental second-line treatment (ie, study 
NCT01843374), 0 otherwise;
• third-line study, which is a dummy variable equal 
to 1 if the patient was involved as a research subject 
in the experimental third-line treatment (ie, study 
NCT02194231), 0 otherwise.
In other words, these variables indicate whether the number 
of cycles, referred to by the previous variables, were supplied 
within a standard clinical pathway or an experimental 
pathway.
Obviously, the total amount of Euros which would be 
reimbursed by the healthcare system to the hospital in 
charge of looking after patients with MPM (total cost) is the 
dependent variable of our multiple regression model. 
Subsequently, using the estimated coefficients of the multiple 
regression model, we calculated the expected cost of treating 
the same patient but adopting different clinical pathways, ie, 
comparing experimental and current treatments. In detail, 
we considered a patient who is 50 years old, with a stage III 
disease, not pre-treated and potentially eligible for Cisplatin-
based chemotherapy. A further condition is for the entire 
clinical pathway to be completed in the same medical center. 
The expected survival time from first medical access is 24 
months. Taking the chemotherapy treatments into account, 
we hypothesized 6 first-line cycles, 4 second-line cycles and, 
finally, 4 more cycles in the third line. Moreover, when we 
simulated the involvement of patients in the experimental 
first-line and maintenance strategies (ie, NCT01907100) 
as well as in the maintenance line (ie, NCT01358084), we 
considered an additional 4 maintenance cycles. 
The proposed comparative simulation considers 5 different 
clinical pathways. Case I assumes all standard treatments 
while the other cases are characterized by a mixed pathway 
with different lines of treatment, ie, both experimental and 
standard treatments. In detail, Case II includes 6 first-line 
cycles plus 4 cycles in the maintenance line, according to 
study NCT01907100, followed by standard treatment in the 
second and third line. Case III proposes standard treatments 
like in case I, plus 4 cycles of experimental treatment in 
the maintenance line according to NCT01358084. Case IV 
entails a mixed experimental strategy, with 6 first-line cycles 
plus 4 cycles in the maintenance line, according to study 
NCT01907100, another 4 cycles of experimental treatment in 
the second line according to study NCT01843374, followed by 
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a final third line with standard treatment (note that 3 patients 
actually followed this mixed strategy). Case V proposes 
standard treatments in the first (6 cycles) and second line (4 
cycles), with an experimental third line of 4 cycles according 
to NCT02194231.
This comparative analysis can shed new light on the impact 
of experimental treatments and/or mixed strategies on 
public finance. The results of the empirical analysis and the 
subsequent simulation are illustrated in the next section.
Results 
From January 1, 2014 to December 31, 2015, 102 patients 
with epithelioid MPM had their first medical examination 
in our hospital; 45 died before the end of data collection 
(30/06/2016) and constitute our selected sample. Note 
that we consider first access to the hospital, which is not 
necessarily the first medical examination after the MPM 
diagnosis, ie, patients might have been previously treated in 
other hospitals and then they chose to access our hospital 
for alternative treatments and/or opinions. Since MPM is a 
rare tumor, the authors believe that the considered sample 
of patients is representative for an empirical investigation of 
this specific case study.1 Table 2 summarizes some descriptive 
demographic statistics about the selected sample of patients, 
highlighting differences between males and females. 
In terms of how far the patients decide to move in order to be 
treated, Table 2 confirms the aforementioned hypothesis of 
greater expected effectiveness of the chosen treatments. On 
average, 22% of the selected sample traveled more than 50 km 
away from their domicile to receive an innovative treatment. 
In detail, 18 patients were treated by our oncology unit from 
the beginning (ie, their first medical access, after the MPM 
diagnosis) up to their death (ie, 40% of the sample). Taking 
the remaining 60% of the sample, the patients were treated in 
other medical centers before they first came to our hospital 
(ie, they had already received some chemotherapy cycles) 
and/or they chose another hospital where to be treated before 
their death.
Table 3 summarizes the average number of treatments offered 
to patients with MPM according to their gender, as well as 
relative average costs. Taking the total sample into account, 
the average cost of treating a patient with MPM is equal to 
€ 8484.69. However, this is an average value which considers 
both the patients that had already been treated in other 
medical centers (ie, non-naïve patient) and the patients that 
left our hospital to be treated in other medical centers (ie, exit 
patient). 
Considering all the patients treated exclusively by the selected 
Table 2. Descriptive Demographic Statistics of the Selected Sample According to Patients’ Gender
Variables Female Male Total Sample
Number of patients 17 28 45
% Of patients who moved to be treated (>50 km) 23.53% 21.43% 22.22%
Average distance between domicile and diagnostic centera 22.781 21.842 22.197
Average distance between domicile and treatment centera 44.641 34.927 38.597
% Of non-naïve patients 35.29% 42.86% 40.00%
% Of Caucasian patients (race) 94.12% 100.00% 97.78%
% Of Latino patients (race) 5.88% 0.00% 2.22%
Average age (at MPM diagnosis)b 64.059 68.821 67.022
Average survival (after MPM diagnosis)c 12.529 12.929 12.778
a Distance expressed in kilometers.
b Time expressed in years.
c Time expressed in months.
Table 3. Descriptive Economic Statistics of the Selected Sample According to Patients’ Gender
Variables Female Male Total Sample
Average number of hospitalizations 0.529 0.357 0.422
Average number of chemotherapy cycles 4.324 5.137 4.830
Average number of follow-up visits 10.647 13.964 12.711
Average number of blood tests 9.941 13.214 11.978
Average number of instrumental exams 8.000 6.929 7.333
% Of patients involved in a first line trial 17.65% 10.71% 13.33%
% Of patients involved in a maintenance line trial 5.88% 7.14% 6.67%
% Of patients involved in a second line trial 11.76% 25.00% 20.00%
% Of patients involved in a third line trial 5.88% 3.57% 4.44%
Average total cost 7810.14 8894.24 8484.69
Average hospitalization cost 6301.10 3843.78 4826.71
Average chemotherapy cost 2993.03 4843.15 4144.22
Average monitoring cost 2241.02 2599.81 2464.27
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independent public hospital from the MPM diagnosis up to 
their death, the average total cost increases to € 15 866.44, with 
average chemotherapy cost equal to € 8813.40 and average 
monitoring cost equal to 4635.04. Note that the monitoring 
cost is given by the sum of follow-up medical visits, blood 
tests, and instrumental exams. 
Supplementary file 1 shows additional economic descriptive 
statistics. In details, Table S1 highlights the per-cycle costs of 
the proposed antitumoral treatments; while Table S2 proposes 
other economic descriptive statistics related to the patients 
and their mobility process. 
Table 4 sets out some descriptive statistics concerning the 
proposed dependent and independent variables of the 
empirical model. Note that a logarithmic transformation is 
applied to the total cost variable.
Table 5 shows the results of the adopted model (column 
1), with the estimated coefficients and (in parentheses) the 
relative robust standard errors. Based on the suggested 
sensitivity analysis, additional model specifications are 
proposed (columns 2-5). 
By observing the results, we can see that the signs of the 
estimated coefficients do not change except in one single case 
(ie, the number of cycles in the second line). This coefficient, 
which is not statistically significant, is positive in the fourth 
model, while it is negative in the previous ones. Although 
there might be concerns regarding this variable, the sensitivity 
analysis confirms the robustness of our results.
Looking at the model proposed in column 1, the F-test 
confirms that it is statistically significant (P < .0000) and the 
R2 value is extremely high (ie, approximately 97% of the total 
cost variability is accounted for by the variables in the model). 
The distribution of residuals is also tested with good results, 
as is the correlation among covariates (ie, mean VIF displays 
a value equal to 4.01) and the pairwise correlation (ie, absence 
of major collinearity issues). 
Considering the coefficients, all the dependent variables 
are statistically significant (P value at least lower than 0.1). 
The only concern is the number of cycles within the second-
line treatment, although the P value obtained is not so poor 
(P < .15). 
Referring to the simulated patient (section 2), Table 6 shows 
the results obtained by comparing the different clinical 
pathways adopted in the simulation.
According to our results, only one case affords significant 
savings in terms of public resources (ie, Case II with expected 
standard cost equal to € 320.18). Therefore, only the clinical 
pathway which includes study NCT01907100, followed by 
standard treatments in the second and third line (ie, Case II), 
has an expected standard spending need lower than a clinical 
pathway based exclusively on standard treatments (ie, Case I). 
In the other cases, the costs borne by the healthcare system to 
treat patients with experimental strategies grow exponentially. 
For example, in case III, even though the drugs are supplied 
free of charge and there is a grant for the required activities 
(€ 5500.00), the standard spending need in order to follow 
this strategy is higher than the expected cost of adopting the 
common treatments (€ 32 495.47 vs. € 18 214.99). How can 
these results be interpreted?
Discussion
As indicated by our results, there is a clear saving of public 
resources in the case of first-line treatments, while the 
Table 4. Descriptive Statistics of Variables Adopted in the Empirical Analysis
Type Variable Obs Mean SD Min Max
Dependent variable Total costa 45 7.3047 2.7141 3.0301 10.7844
Control variables
Time (age) 45 67.0222 11.5552 28.0000 85.0000
Time (survival) 45 8.7111 5.8954 0.0000 23.0000
Non-naïve patient 45 0.4000 0.4954 0.0000 1.0000
Exit patient 45 0.4222 0.4995 0.0000 1.0000
Cancer stage 45 3.0444 0.6013 2.0000 4.0000
Side effects tolerability 45 0.2667 0.4472 0.0000 1.0000
Explanatory variables
Hospitalizations 45 0.4222 0.6905 0.0000 2.0000
First line (cycles) 45 0.3260 0.4221 0.0000 1.0000
Maintenance (cycles) 45 0.7851 2.0997 0.0000 8.0000
Second line (cycles) 45 1.2222 1.9672 0.0000 9.0000
Third line (cycles) 45 0.5444 1.5368 0.0000 7.5000
Standard treatments (quota) 45 0.4340 0.4557 0.0000 1.0000
Maintenance study 45 0.0667 0.2523 0.0000 1.0000
First-line study 45 0.1333 0.3438 0.0000 1.0000
Second-line study 45 0.2000 0.4045 0.0000 1.0000
Third-line study 45 0.0444 0.2084 0.0000 1.0000
a Logarithmic transformation.
Data were extracted from the dataset of the analyzed general hospital, applying the current reimbursement system of the regional system.
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following lines are characterized by a higher economic burden. 
This is mainly due to the current price of chemotherapy drugs, 
operative costs and toxicity of experimental treatments. 
Indeed, the cost of first-line chemotherapy is considerable, 
whereas the cost of the subsequent lines is lower. At the same 
time, there was a higher toxicity level at second and at third 
line, as well as a higher number of diagnostic and blood 
examinations. The economic gap between traditional and 
experimental treatments is crucial in the compensation of the 
higher operating costs due to the increased number of medical 
activities required by a clinical trial, as well as the necessary 
treatments to face the unexpected toxicity. For example, 
Table 5. OLS Regression Model - Robust Option: Cost Components of Treating MPM
Variables
(1) (2) (3) (4) (5)
Total Costa Total Costa Total Costa Total Costa Total Costa
Time (age) -0.0354**
(0.0155)
Time (survival) 0.118***
(0.0262)
Non-naïve patient 0.557* 0.290
(0.284) (0.392)
Exit patient -1.846*** -0.783**
(0.345) (0.300)
Cancer stage -1.030*** -0.715*** -0.627***
(0.215) (0.219) (0.219)
Side effects tolerability -0.841** -0.790** -0.715**
(0.348) (0.328) (0.295)
Hospitalizations 1.139*** 0.940*** 0.843*** 0.570*
(0.189) (0.214) (0.308) (0.320)
First line (cycles) 1.283** 1.562** 1.378*** 1.767***
(0.499) (0.643) (0.416) (0.575)
Maintenance (cycles) -0.336*** -0.156 -0.176 -0.135
(0.0904) (0.120) (0.132) (0.154)
Second line (cycles) -0.117 -0.00917 -0.00203 0.0407
(0.0785) (0.0942) (0.106) (0.101)
Third line (cycles) -0.563*** -0.650*** -0.667*** -0.630***
(0.124) (0.141) (0.152) (0.176)
Standard treatments (quota) 3.131*** 3.749*** 4.167*** 3.686*** 4.313***
(0.446) (0.402) (0.296) (0.531) (0.419)
First-line study 2.775*** 2.800** 3.398*** 2.826** 3.340***
(0.735) (1.120) (1.207) (1.167) (0.489)
Maintenance study 2.212*** 3.056*** 3.429*** 2.444*** 1.871**
(0.729) (0.591) (0.608) (0.723) (0.750)
Second-line study 2.998*** 3.683*** 4.067*** 3.942*** 3.108***
(0.516) (0.519) (0.530) (0.639) (0.642)
Third-line study 2.084*** 2.862*** 3.361*** 3.702*** 4.119***
(0.551) (0.571) (0.759) (0.584) (0.398)
Constant 9.846*** 6.403*** 5.647*** 3.821*** 4.156***
(1.673) (0.872) (0.748) (0.258) (0.289)
Observations 45 45 45 45 45
R-squared 0.971 0.950 0.937 0.919 0.818
Abbreviations: MPM, malignant pleural mesothelioma; OLS, ordinary least squares.
Robust standard errors in parentheses.
*** P < .01, ** P < .05, * P < .1.
a Logarithmic transformation.
Table 6. Expected Cost of Caring for Patients Affected by MPM According to Different Clinical Pathways
A B C D E (A+B+C+D-E)
Clinical Pathways Hospitalizations First Line Second Line Third Line Expected Grant Standard Cost
Case I 5353.55 8112.46 4030.73 718.24 - 18 214.99
Case II 2457.99 3320.73 1681.17 160.30 7300.00 320.18
Case III 10 388.63 19 823.95 7105.41 677.48 5500.00 32 495.47
Case IV 19 538.61 26 396.52 28 964.85 1274.19 36 050.00 40 124.18
Case V 15 685.68 23 769.15 11 809.87 8575.24 - 59 839.94
Abbreviation: MPM, malignant pleural mesothelioma.
Ippoliti et al
International Journal of Health Policy and Management, 2018, 7(8), 728–737 735
considering a patient with body surface area (BSA) equal to 1.8 
mt2, a cycle of cisplatin plus pemetrexed costs € 2398.79 (first-
line treatment), while a cycle of Carboplatin plus pemetrexed 
costs € 2408.10 (first-line treatment). In the second or third 
line, the same patient might be treated with vinorelbine, 
costing € 71.50 for every cycle, or gemcitabine, costing € 37.00 
for every cycle, or carboplatin plus gemcitabine, costing € 
59.27 for every cycle (see Table S2 in Supplementary file 1). 
At the same time, the number of medical investigations for 
a patient involved in an experimental second-line treatment 
would increase dramatically. For example, assuming 6 cycles 
of chemotherapy and a patient involved in a second-line trial 
(ie, NCT01843374), we can expect the patient to access the 
hospital 12 times, with blood tests and medical checks, as well 
as 2 computerized axial tomography (CAT) scans, 1 positron 
emission tomography (PET) and 7 X-rays. Considering the 
same patient but treated according to a traditional clinical 
second-line protocol (ie, vinorelbine), we can expect the 
patient to access the hospital 12 times, with blood tests 
and medical checks, but the number of other diagnostic 
investigations would be lower (ie, 1 CAT scan, 3 X-rays and 
1 electrocardiogram). If we consider the toxicity level, at 
present we cannot support the hypothesis that experimental 
drugs at second and third level have lower tolerability, since 
we need to wait for the publication of official reports by the 
sponsors about collected toxicity data. However, we cannot 
reject this hypothesis a priori since it is coherent with the 
current knowledge. 
Therefore, our results clearly show the economic impact of 
experimental treatments in subsequent lines, ie, after the 
first (expensive) line. Indeed, these experimental treatments 
might lead to an increase in operating and hospitalization 
costs, without a significant drug cost saving. Moreover, the 
higher operating costs are not completely compensated for 
by the grants offered, which means that hospital managers 
should carefully consider whether to be involved in a clinical 
trial, comparing grants with all expected costs. What about 
the other variables?
According to our results, we can expect a patient’s health 
status upon first medical access to be a significant driver of 
cost, since an expected higher number of medical treatments 
will be provided by the regional healthcare system. Indeed, 
the older the patient and/or the more advanced the stage 
of cancer, the lower the final expected costs borne by the 
regional healthcare system (ie, statistically significant negative 
coefficients), which is mainly due to the lower number of 
medical activities in terms of diagnostic examinations. This 
result is coherent with the survival time (ie, statistically 
significant positive coefficient), that is to say, the longer the 
expected patient’s survival time, the higher the expected costs 
borne by the regional healthcare system. Therefore, although 
the current scientific knowledge does not provide a strategy 
to defeat MPM, patients are involved in very intensive 
clinical protocols, which become extremely expensive. 
Moreover, mainly due to the high toxicity level of the drugs 
used, hospitalization is needed multiple times, which can 
be considered one of the main drivers of cost in oncology 
units (ie, statistically significant positive coefficient). This 
hypothesis is supported by the variable adopted to capture 
side effects tolerability, which can reduce the final cost 
of treating patients with MPM (ie, statistically significant 
negative coefficient). Indeed, the ability to tolerate the high 
toxicity of chemotherapy drugs can be crucial in limiting the 
need for supportive care.
Study Limitations
The main limits of this study concern the sample, which is 
quite small (ie, 45 patients), and the available information. On 
the one hand, the sample comprises the most critical patients, 
that is to say, the patients who died before the end of data 
collection. On the other hand, many patients were involved 
in clinical trials and complete information is not currently 
available (eg, whether these subjects received placebo or 
experimental treatments). Another limit relates to the 
proposed hypothesis behind the adopted costs. Indeed, the 
fees used as reimbursements by the Local Health Authorities 
represent our reference costs, assuming that a competitive 
market drives the health providers toward those standard 
costs (ie, those efficiency levels). Obviously, there are risks of 
overestimation in our results if the real cost is lower than the 
fee (ie, the hospital is more efficient than the standard level) or 
underestimation if the real cost is higher than the fee (ie, the 
hospital is less efficient than the standard level). Therefore, 
these results should be taken with a degree of caution and 
they cannot be generalized. 
Despite the above limitations, this study may represent a 
solid first step for a broader and deeper analysis of the topic. 
Indeed, our work can stimulate the debate on the economic 
impact of human experimentation among policy-makers, 
hospital managers, and physicians. 
Future research will be aimed at confirming the results of this 
pilot study by involving other hospitals specialized in MPM 
care, thus significantly increasing the sample size. At the same 
time, the authors will try to extend the methodology applied 
here to include other types of cancer (eg, head and neck 
cancer), so as to validate the proposed approach and highlight 
whether differences might exist. 
Conclusion
This is an empirical, retrospective analysis focusing on a 
reference hospital specialized in MPM care. This hospital 
is a forefront medical reference center in the North West of 
Italy, assisting MPM patients from the main polluted area 
(ie, Casale Monferrato), as well as other relevant areas (ie, 
Cavagnola and Broni). In detail, we conducted a retrospective 
cost analysis on all the patients with MPM who first accessed 
the hospital between 2014 and 2015; collecting data about 
their diagnostic pathways and active treatments, as well as the 
related official fees for each procedure. Then, using a multiple 
regression model, we estimated the overall expected cost of 
a patient with MPM treated in our hospital, which would be 
borne by the regional healthcare system based on the clinical 
pathways. 
Our results confirm that drug cost avoidance might be 
positive but, in order to properly estimate the economic 
impact of clinical trials on public healthcare systems, we also 
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need to consider alternative standard treatments along the 
entire clinical pathway of the research subjects. Indeed, our 
results indicate that experimental trials might be a solution 
to reduce the economic burden placed on public healthcare 
systems only in the case of first-line treatments, where the 
cost of chemotherapy is substantial. For what concerns 
second-line and third-line treatments, even if the drugs 
were supplied to the medical centers by the sponsor for free, 
there would be no opportunities to save money since, as our 
analysis shows, the regional healthcare system would have to 
bear higher costs. This means that, in the second and third 
line, although experimental treatments might represent an 
opportunity to increase scientific knowledge and the research 
subjects’ expected survival time, society has to share with 
pharmaceutical companies a portion of the costs needed to test 
the proposed innovations and, by doing so, to collect clinical 
evidence. Therefore, in order to expand medical knowledge, 
society needs not only to accept the pharmaceutical 
companies’ market power (ie, monopoly) and a part of the 
adverse risks linked to clinical research9 but also to bear 
the additional economic costs related to the testing phase. 
Moreover, patient costs should not be forgotten. According 
to current literature, clinical trials involving cancer patients 
entail the added cost of more frequent clinical checkups 
and additional tests.22,32,33 Only if the patients accept to bear 
all expected adverse risks and additional costs, signing the 
informed consent form, and the hospital management decides 
to face the additional economic burden, signing the contract, 
will the investment be made, since a profit is foreseeable. On 
the other hand, pharmaceutical companies will deal with all 
unexpected adverse events and bear the other portion of the 
costs needed to treat the research subjects (ie, supplying free 
drugs and grants). The risk and cost sharing idea relies on 
the distribution of adverse events and costs among the parties 
(ie, patients, hospitals, and pharmaceutical companies), and 
the present study sheds some new light on this relevant topic. 
Society should consider its involvement in clinical trials with 
particular attention, properly balancing costs and risks, but 
this is the price to be paid if we want to win the battle against 
MPM.
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